Three-Dimensional Evaluation of Static and Dynamic Effects of Botulinum Toxin A on Glabellar Frown Lines
- 138 Downloads
The use of injectable solutions for aesthetic purposes has increased tremendously, but lacks objective support. We aimed at assessing static and dynamic effects of botulinum toxin A (BoNTA) on glabellar lines by use of an objective three-dimensional methodology.
We prospectively collected three-dimensional stereographic photographs of two different facial expressions (pretreatment, 30 and 90 days posttreatment) in 21 patients, receiving a total of 20 units of BoNTA in both corrugator supercilii muscles. The primary endpoint was the three-dimensional static and dynamic surface irregularity, and secondary endpoints were the glabellar line scale and overall patient satisfaction. Blinded retrospective data analysis and statistical evaluation were performed with p < 0.05 considered statistically significant.
Static glabellar lines (neutral facial expression) were significantly reduced by − 17% and − 24% on day 30 and 90 posttreatment, respectively (vs. pretreatment; both p < 0.0001). Dynamic glabellar frown lines (firmest possible bilateral eye closure) demonstrated a reduction of surface irregularity by − 26% and − 21% on day 30 and 90 posttreatment, respectively (vs. pretreatment; both p < 0.0001). The subjective dynamic glabellar line scale documented a statistically significant improvement on day 30 posttreatment (mean ± SD: 1.5 ± 0.8; p < 0.05) versus pretreatment (2.8 ± 1.0). Polled patients confirmed a subjective wrinkle improvement 90 days posttreatment.
The presented setup detected even subtle changes of BoNTA treatment for facial wrinkling and is a promising asset for scientific evaluations of clinical studies analyzing the outcome and duration of efficacy of injectable solutions on the face.
Level of Evidence IV
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
KeywordsRejuvenation Facial Botox Objective Three-dimensional
All authors made substantial contributions to the conception and design (DBL, TR, PW), data acquisition (DP, PW), analysis (DBL, ACT, PW), interpretation (ACT, DBL, SM, TR, PW, LPK), drafting of the manuscript and its revision for important intellectual content (all authors).
Dr. Thomas Rappl provided the botulinum toxin for the treatment of the glabellar lines.
Compliance with ethical standards
Conflict of interest
Dr. Thomas Rappl is a consultant and investigator to Merz Pharmaceuticals GmbH, Germany. All the other authors have no conflict of interest to declare.
- 1.De Boulle K, Fagien S, Sommer B, Glogau R (2010) Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101–118Google Scholar
- 2.Research C for DE and Press Announcements - FDA approves Botox Cosmetic to improve the appearance of crow’s feet lines. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367662.htm. Accessed 8 Aug 2015
- 3.(2015) 2014 Plastic Surgery Statistics In: American Society of Plastic Surgeons http://www.plasticsurgery.org/Documents/news-resources/statistics/2014-statistics/cosmetic-procedure-trends-2014.pdf. Accessed 7 June 2017
- 6.Hexsel D, Soirefmann M, Porto MD et al (2015) Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al 41(Suppl 1):S110–S118. https://doi.org/10.1097/01.DSS.0000452645.76270.88 Google Scholar
- 8.Carruthers A, Sadick N, Brandt F et al (2015) Evolution of facial aesthetic treatment over five or more years: a retrospective cross-sectional analysis of continuous onabotulinumtoxinA treatment. Dermatol Surg Off Publ Am Soc Dermatol Surg Al 41:693–701. https://doi.org/10.1097/DSS.0000000000000340 Google Scholar
- 10.Carruthers JDA, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty (2008) Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies–consensus recommendations. Plast Reconstr Surg 121:5S–30S. https://doi.org/10.1097/prs.0b013e31816de8d0 (quiz 31S–36S) CrossRefGoogle Scholar
- 12.Upper face. In: Merz Aesthet. https://www.merzaesthetics.com/services/scales/upper-face/. Accessed 21 Oct 2015
- 15.Lewis C (2002) Botox cosmetic: a look at looking good. FDA Consum 36:11–13Google Scholar
- 17.Carruthers J, Rivkin A, Donofrio L et al (2015) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow’s feet lines and glabellar lines. Dermatol Surg Off Publ Am Soc Dermatol Surg Al 41:702–711. https://doi.org/10.1097/DSS.0000000000000357 Google Scholar
- 22.Verzé L, Bianchi FA, Ramieri G (2014) Three-dimensional laser scanner evaluation of facial soft tissue changes after LeFort I advancement and rhinoplasty surgery: patients with cleft lip and palate vs patients with nonclefted maxillary retrognathic dysplasia (control group). Oral Surg Oral Med Oral Pathol Oral Radiol 117:416–423. https://doi.org/10.1016/j.oooo.2013.12.406 CrossRefGoogle Scholar